Viral suppression off ART using dual bNAb therapy
RIO Arm C is now closed to recruitment!
We are pleased to announce that the new RIO study arm is also now closed to recruitment.
This arm is called “Arm C”. Arm C will aim to understand the viral rebound dynamics between the first and second analytical treatment interruptions (ATIs) in people with HIV who started ART at the time of primary or early-stage HIV Infection. With Arm C, we are looking at how best to boost the immune system and make the bNAb effect last as long as possible.
Main RIO trial primary results are available!
The RIO trial completed recruitment to the first part of the trial in July 2024. This was a randomised controlled trial where individuals enrolling were allocated to receive a masked (“blinded”) drip containing either broadly neutralising antibodies (bNAbs) or placebo (saline). The results of this part of the trial were presented at the CROI conference, San Francisco, on 10th March 2025.
NEW: Final interview with RIO trial participant
In this final installment filmed in May 2026, we check in once more with our RIO trial participant. Having previously spoken with Professor Sarah Fidler at the start of the study in 2023 and again mid-trial in 2025, they now sit down with RIO investigator Dr. Tamara Elliott. In this interview, the participant discusses their experience receiving bNAb infusions (Arm A), reflects on the viral rebound process, and shares their perspective on returning to treatment.
Latest News
- Primary outcome paper by RIO study team shows new HIV treatment could suppress the HIV virus for monthsMeesha Patel, 27 May 2026, Imperial College London RIO trial shows a new HIV treatment (broadly neutralising antibody therapy) enables […]
- Aidsmap interview with Professor John Frater at CROI ConferenceGus Cairns from Aidsmap reported from the CROI conference, Denver 22-25 February 2026 following results showing that half the participants […]
- RIO Trial featured by Nature Medicine as one of the clinical trials shaping medicine in 2026RIO Trial Featured by Nature Medicine as One of the Clinical Trials Shaping Medicine in 2026 We’re thrilled to announce […]
RIO is funded by the Bill & Melinda Gates Foundation. Imperial College London is the Trial Sponsor and the trial is coordinated by Imperial College London, The University of Oxford and The Rockefeller University.
